<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00287131</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-04-3518-JS-CTIL</org_study_id>
    <nct_id>NCT00287131</nct_id>
  </id_info>
  <brief_title>Adoptive Cell Therapy Following Non-myeloablate Chemotherapy in Metastatic Melanoma Patients</brief_title>
  <official_title>Adoptive Cell Therapy Following Non-myeloablate Chemotherapy in Metastatic Melanoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Metastatic melanoma is an aggressive and highly malignant cancer. The five-year survival rate
      of patients with metastatic disease is less than 5% with a median survival of only 6-10
      months. Drugs like Dacarbazin (DTIC) as a single agent or in combination with other
      chemotherapy agents, have a response rate of 15-30%, but the duration of response is usually
      short, with no impact on survival. Interleukin-2 (IL-2) based immunotherapy has shown more
      promising results. This form of therapy has a similar response rate with some patients
      achieving a durable complete response. Recently the National Institute of Health (NIH)
      reported that by using lympho-depleting chemotherapy, followed by an adoptive transfer of
      large numbers of anti-tumor specific tumor-infiltrating lymphocytes (TIL), an objective
      regression was achieved in 51% of patients with metastatic melanoma.

      Objectives: To introduce the TIL technology to advanced metastatic melanoma patients in
      Israel.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2006</start_date>
  <completion_date type="Anticipated">November 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate and toxicity</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Metastatic Melanoma</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Procedure - Adoptive cell transfer</intervention_name>
    <description>Procedure - Adoptive cell transfer</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metastatic Melanoma patients failing to prior chemo and immunotherapy with good
             performance status.

        Exclusion Criteria:

          -  Brain mets
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacob Schachter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head, Ella Institute, Sheba Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacob Schachter, MD</last_name>
    <phone>972-3-5304907</phone>
    <email>Jacob.Schachter@sheba.health.gov.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aviad Yair</last_name>
    <phone>972-543355595</phone>
    <email>Aviad.Yair@sheba.health.gov.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacob Schachter, MD</last_name>
      <phone>972-3-5304907</phone>
      <email>Jacob.Schachter@sheba.health.gov.il</email>
    </contact>
    <contact_backup>
      <last_name>Aviad Yair</last_name>
      <phone>972-543355595</phone>
      <email>Aviad.Yair@sheba.health.gov.il</email>
    </contact_backup>
    <investigator>
      <last_name>Jacob Schachter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <results_reference>
    <citation>Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, Levy D, Kubi A, Hovav E, Chermoshniuk N, Shalmon B, Hardan I, Catane R, Markel G, Apter S, Ben-Nun A, Kuchuk I, Shimoni A, Nagler A, Schachter J. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2010 May 1;16(9):2646-55. doi: 10.1158/1078-0432.CCR-10-0041. Epub 2010 Apr 20.</citation>
    <PMID>20406835</PMID>
  </results_reference>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2006</study_first_submitted>
  <study_first_submitted_qc>February 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2006</study_first_posted>
  <last_update_submitted>March 28, 2012</last_update_submitted>
  <last_update_submitted_qc>March 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>melanoma</keyword>
  <keyword>metastatic melanoma</keyword>
  <keyword>adoptive immunotherapy</keyword>
  <keyword>IL-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

